Induction of oral tolerance to cellular immune responses in the absence of Peyer's patches. 2001

T W Spahn, and A Fontana, and A M Faria, and A J Slavin, and H P Eugster, and X Zhang, and P A Koni, and N H Ruddle, and R A Flavell, and P D Rennert, and H L Weiner
Center for Neurologic Diseases, Brigham and Women's Hospital and Harvard Medical School, Boston, USA.

Systemic hyporesponsiveness occurs following oral administration of antigen (oral tolerance) and involves the uptake and processing of antigen by the gut-associated lymphoid tissue (GALT), which includes Peyer's patches (PP) lamina propria lymphocytes and mesenteric lymph nodes (MLN). Animals with targeted mutations of genes in the tumor necrosis factor (TNF) family have differential defects in the development of peripheral lymphoid organs including PP and MLN, and provide a unique opportunity to investigate the role of GALT structures in the induction of oral tolerance. Oral tolerance could not be induced in TNF/lymphotoxin (LT) alpha-/- mice, which are devoid of both PP and MLN, although these animals could be tolerized by intraperitoneal administration of antigen, demonstrating the requirement for GALT for oral tolerance induction. LTbeta-/- mice and LTalpha/LTbeta+/- animals do not have PP but could be orally tolerized, as measured by IFN-gamma production and delayed-type hypersensitivity responses by administration of both low or high doses of ovalbumin. To further investigate the requirement for PP, we tested the progeny of LTbeta-receptor-IgG-fusion-protein (LTbetaRigG)-treated mice, which do not form PP but have an otherwise intact immune system. Although these animals had decreased fecal IgA production, they could be orally tolerized. Our results demonstrate that PP are not an absolute requirement for the induction of either high- or low-dose oral tolerance, although oral tolerance could not be induced in animals devoid of both PP and MLN.

UI MeSH Term Description Entries
D006968 Hypersensitivity, Delayed An increased reactivity to specific antigens mediated not by antibodies but by sensitized T CELLS. Hypersensitivity, Tuberculin-Type,Hypersensitivity, Type IV,Tuberculin-Type Hypersensitivity,Type IV Hypersensitivity,Delayed Hypersensitivity,Delayed Hypersensitivities,Hypersensitivity, Tuberculin Type,Tuberculin Type Hypersensitivity,Tuberculin-Type Hypersensitivities,Type IV Hypersensitivities
D007070 Immunoglobulin A Represents 15-20% of the human serum immunoglobulins, mostly as the 4-chain polymer in humans or dimer in other mammals. Secretory IgA (IMMUNOGLOBULIN A, SECRETORY) is the main immunoglobulin in secretions. IgA,IgA Antibody,IgA1,IgA2,Antibody, IgA
D007108 Immune Tolerance The specific failure of a normally responsive individual to make an immune response to a known antigen. It results from previous contact with the antigen by an immunologically immature individual (fetus or neonate) or by an adult exposed to extreme high-dose or low-dose antigen, or by exposure to radiation, antimetabolites, antilymphocytic serum, etc. Immunosuppression (Physiology),Immunosuppressions (Physiology),Tolerance, Immune
D007371 Interferon-gamma The major interferon produced by mitogenically or antigenically stimulated LYMPHOCYTES. It is structurally different from TYPE I INTERFERON and its major activity is immunoregulation. It has been implicated in the expression of CLASS II HISTOCOMPATIBILITY ANTIGENS in cells that do not normally produce them, leading to AUTOIMMUNE DISEASES. Interferon Type II,Interferon, Immune,gamma-Interferon,Interferon, gamma,Type II Interferon,Immune Interferon,Interferon, Type II
D007376 Interleukin-2 A soluble substance elaborated by antigen- or mitogen-stimulated T-LYMPHOCYTES which induces DNA synthesis in naive lymphocytes. IL-2,Lymphocyte Mitogenic Factor,T-Cell Growth Factor,TCGF,IL2,Interleukin II,Interleukine 2,RU 49637,RU-49637,Ro-23-6019,Ro-236019,T-Cell Stimulating Factor,Thymocyte Stimulating Factor,Interleukin 2,Mitogenic Factor, Lymphocyte,RU49637,Ro 23 6019,Ro 236019,Ro236019,T Cell Growth Factor,T Cell Stimulating Factor
D008198 Lymph Nodes They are oval or bean shaped bodies (1 - 30 mm in diameter) located along the lymphatic system. Lymph Node,Node, Lymph,Nodes, Lymph
D008233 Lymphotoxin-alpha A tumor necrosis factor family member that is released by activated LYMPHOCYTES. Soluble lymphotoxin is specific for TUMOR NECROSIS FACTOR RECEPTOR TYPE I; TUMOR NECROSIS FACTOR RECEPTOR TYPE II; and TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY, MEMBER 14. Lymphotoxin-alpha can form a membrane-bound heterodimer with LYMPHOTOXIN-BETA that has specificity for the LYMPHOTOXIN BETA RECEPTOR. TNF Superfamily, Member 1,TNF-beta,Tumor Necrosis Factor Ligand Superfamily Member 1,Tumor Necrosis Factor-beta,Lymphotoxin,Lymphotoxin-alpha3,Soluble Lymphotoxin-alpha,alpha-Lymphotoxin,Lymphotoxin alpha,Lymphotoxin alpha3,Lymphotoxin-alpha, Soluble,Soluble Lymphotoxin alpha,Tumor Necrosis Factor beta,alpha Lymphotoxin
D008807 Mice, Inbred BALB C An inbred strain of mouse that is widely used in IMMUNOLOGY studies and cancer research. BALB C Mice, Inbred,BALB C Mouse, Inbred,Inbred BALB C Mice,Inbred BALB C Mouse,Mice, BALB C,Mouse, BALB C,Mouse, Inbred BALB C,BALB C Mice,BALB C Mouse
D008810 Mice, Inbred C57BL One of the first INBRED MOUSE STRAINS to be sequenced. This strain is commonly used as genetic background for transgenic mouse models. Refractory to many tumors, this strain is also preferred model for studying role of genetic variations in development of diseases. Mice, C57BL,Mouse, C57BL,Mouse, Inbred C57BL,C57BL Mice,C57BL Mice, Inbred,C57BL Mouse,C57BL Mouse, Inbred,Inbred C57BL Mice,Inbred C57BL Mouse
D010047 Ovalbumin An albumin obtained from the white of eggs. It is a member of the serpin superfamily. Serpin B14

Related Publications

T W Spahn, and A Fontana, and A M Faria, and A J Slavin, and H P Eugster, and X Zhang, and P A Koni, and N H Ruddle, and R A Flavell, and P D Rennert, and H L Weiner
June 1986, Immunology,
T W Spahn, and A Fontana, and A M Faria, and A J Slavin, and H P Eugster, and X Zhang, and P A Koni, and N H Ruddle, and R A Flavell, and P D Rennert, and H L Weiner
December 2001, Immunobiology,
T W Spahn, and A Fontana, and A M Faria, and A J Slavin, and H P Eugster, and X Zhang, and P A Koni, and N H Ruddle, and R A Flavell, and P D Rennert, and H L Weiner
March 2001, Proceedings of the National Academy of Sciences of the United States of America,
T W Spahn, and A Fontana, and A M Faria, and A J Slavin, and H P Eugster, and X Zhang, and P A Koni, and N H Ruddle, and R A Flavell, and P D Rennert, and H L Weiner
January 2002, Pathobiology : journal of immunopathology, molecular and cellular biology,
T W Spahn, and A Fontana, and A M Faria, and A J Slavin, and H P Eugster, and X Zhang, and P A Koni, and N H Ruddle, and R A Flavell, and P D Rennert, and H L Weiner
June 1983, Annals of the New York Academy of Sciences,
T W Spahn, and A Fontana, and A M Faria, and A J Slavin, and H P Eugster, and X Zhang, and P A Koni, and N H Ruddle, and R A Flavell, and P D Rennert, and H L Weiner
January 1995, Revista latinoamericana de microbiologia,
T W Spahn, and A Fontana, and A M Faria, and A J Slavin, and H P Eugster, and X Zhang, and P A Koni, and N H Ruddle, and R A Flavell, and P D Rennert, and H L Weiner
February 2008, Gastroenterology,
T W Spahn, and A Fontana, and A M Faria, and A J Slavin, and H P Eugster, and X Zhang, and P A Koni, and N H Ruddle, and R A Flavell, and P D Rennert, and H L Weiner
May 2001, Trends in immunology,
T W Spahn, and A Fontana, and A M Faria, and A J Slavin, and H P Eugster, and X Zhang, and P A Koni, and N H Ruddle, and R A Flavell, and P D Rennert, and H L Weiner
January 1975, Biologie et gastro-enterologie,
T W Spahn, and A Fontana, and A M Faria, and A J Slavin, and H P Eugster, and X Zhang, and P A Koni, and N H Ruddle, and R A Flavell, and P D Rennert, and H L Weiner
August 1987, Scandinavian journal of immunology,
Copied contents to your clipboard!